TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Geriatrician Nathaniel Chin argues that persistent concerns about memory or thinking can merit assessment even when cognitive test scores remain normal. Subjective cognitive decline is not a diagnosis of Alzheimer’s; its causes vary, and the article says repeated testing and, for selected patients, biomarkers may help guide evaluation.
Geriatrician Nathaniel Chin says people who report persistent changes in memory or thinking may warrant a more thorough assessment even when cognitive testing remains within the normal range. In an article published by Being Patient on October 27, 2026, he describes subjective cognitive decline as a possible early window for evaluating risk and other causes—not as evidence by itself that someone has Alzheimer’s disease.
Subjective cognitive decline (SCD) refers to a person’s lasting sense that their cognitive abilities have fallen from an earlier level, despite testing that does not show objective impairment. Chin says that a normal result can miss a meaningful change because standard comparisons usually measure a person against others of similar age, not against their own past performance. Someone whose abilities were once well above average could decline and still score within the average range.
Chin distinguishes a short screening test from a comprehensive cognitive evaluation. Screenings commonly take five to 15 minutes and sample a limited range of abilities; a fuller evaluation can take an hour or more and examine memory, language, attention and executive function. A careful assessment helps determine whether objective impairment is already present and provides a baseline for later comparison.
He recommends looking for other explanations as well as monitoring change. Sleep problems, medications, depression or anxiety, illness, vascular disease, hearing loss and stress can affect how a person experiences their thinking. For selected patients, Chin says, blood tests for biomarkers, cerebrospinal fluid testing or amyloid PET may help assess whether Alzheimer’s-related biological changes are present. The article does not report a new study or make a claim that these tests are appropriate for everyone with SCD.
Why Normal Scores May Not End Follow-Up
For patients and families, Chin’s central point is that normal test results do not necessarily settle a persistent concern. A person’s everyday experience and observations from people who know them may add information that a single score cannot capture. Establishing a baseline and repeating assessments can help clinicians distinguish a stable pattern from continuing decline, including changes that have not yet crossed a threshold for impairment.
This approach may also help keep the conversation focused on more than Alzheimer’s. Because SCD has multiple possible causes, evaluating sleep, mood, medications, hearing and medical conditions can identify issues that may be contributing to symptoms. Biomarker testing may provide additional information in selected cases, but the article presents it as one consideration within clinical evaluation, not as a universal screening recommendation or a way to predict an individual’s future with certainty.
Products Worth Considering
Blueair Blue Pure 511i Max Air Purifier for Home and Bedroom
Philips Hue Large Smart Light Tube, Black – White and Color Ambiance LED Color-Changing Light – 1 Pack
Roborock Q7 M5+ Robot Vacuum and Mop
As an affiliate, we earn on qualifying purchases.
How Clinicians Define SCD
Chin is a memory-care physician at UW Health and an associate professor in the University of Wisconsin–Madison’s Department of Medicine. He serves as medical director and Clinical Core co-leader of the Wisconsin Alzheimer’s Disease Research Center. His article is a physician’s perspective on clinical assessment, rather than a report of newly published research findings.
The article describes the “SCD-plus” features developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. These include memory-focused concerns, onset within the past five years, onset at age 60 or older, worry about the change, persistence, seeking medical help and confirmation by someone who knows the person well. Chin stresses that none of these features proves Alzheimer’s disease; several occurring together may support closer attention.
He contrasts a person with longstanding, intermittent word-finding worries linked to stress or poor sleep with someone in their 60s reporting a clear, persistent memory change over two years, shared by a spouse and serious enough to prompt an evaluation. Both could score normally, he says, but the circumstances would lead him to consider their cases differently.
What SCD Can—and Cannot—Show
SCD does not establish that Alzheimer’s is present, and the features associated with SCD-plus are indicators for attention, not proof. The article lists several other factors that can influence perceived thinking, but it does not quantify how often SCD reflects Alzheimer’s rather than another cause or provide an individual risk estimate.
The source material also does not specify which patients should receive blood biomarker, cerebrospinal fluid or amyloid PET testing, how clinicians should choose among them, or what results would mean for a particular person’s care. Chin frames those tests as questions for selected patients. It remains unclear from the article what prevention or treatment steps follow from a positive biomarker result when someone has no measurable cognitive impairment.
Building a Baseline and Rechecking
Chin’s proposed clinical response is to establish a thorough baseline, check for other contributors and, when possible, gather observations from someone familiar with the patient’s day-to-day abilities. Follow-up testing can show whether reported concerns remain stable or develop into a consistent measurable decline. The article does not set a standard interval for repeat testing.
For readers concerned about a persistent change, the piece supports raising it with a qualified health professional rather than treating SCD as a self-diagnosis. The next steps depend on a person’s history, evaluation and possible contributing factors. Whether Alzheimer’s biomarkers are appropriate is a clinical decision; the article makes no announcement of a new test, treatment or prevention program.
Key Questions
Does subjective cognitive decline mean someone has Alzheimer’s?
No. SCD describes a persistent perception of cognitive change despite testing that does not show objective impairment. Chin says it does not identify the cause; Alzheimer’s is one possibility among several.
Can a normal cognitive test miss a change?
It can, according to Chin. Many tests compare people with others of similar age rather than with their own earlier abilities, and brief screenings assess only a limited sample of cognition. A detailed baseline and follow-up may offer more information over time.
What are SCD-plus features?
They are features that may make subjective decline more concerning, including memory-focused and persistent change, onset at age 60 or older, worry, seeking medical help and confirmation by someone familiar with the person. They do not prove Alzheimer’s disease.
Can biomarkers detect Alzheimer’s before impairment?
Chin says blood biomarkers, cerebrospinal fluid testing and amyloid PET can help assess Alzheimer’s-related biological changes in selected patients. The article does not say these tests should be used for everyone with SCD or specify who should receive them.
What else can affect how sharp thinking feels?
The article lists sleep problems, medications, depression or anxiety, medical illness, vascular disease, hearing loss, stress and normal aging as possible contributors. A clinician can assess the circumstances and consider appropriate evaluation.
Source: beingpatient.com
